S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind

AxoGen Stock Price, News & Analysis (NASDAQ:AXGN)

$7.15
+0.27 (+3.92%)
(As of 12/4/2023 ET)
Compare
Today's Range
$6.83
$7.17
50-Day Range
$3.61
$6.88
52-Week Range
$3.45
$11.32
Volume
304,815 shs
Average Volume
299,316 shs
Market Capitalization
$307.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

AxoGen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
109.8% Upside
$15.00 Price Target
Short Interest
Bearish
5.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of AxoGen in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$62,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

471st out of 952 stocks

Medical Devices Industry

3rd out of 9 stocks


AXGN stock logo

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

AXGN Stock News Headlines

AxoGen, Inc. (NASDAQ:AXGN) Sees Large Increase in Short Interest
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
AxoGen (NASDAQ:AXGN) Lowered to "Hold" at StockNews.com
Axogen Inc AXGN
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Axogen, Inc. Reports 2023 Third Quarter Financial Results
Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023
AxoGen Q3 2023 Earnings Preview
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
JMP Securities Remains a Buy on AxoGen (AXGN)
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
AxoGen (NASDAQ: AXGN)
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/12/2024

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
394
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+109.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,950,000.00
Pretax Margin
-15.26%

Debt

Sales & Book Value

Annual Sales
$138.58 million
Book Value
$2.39 per share

Miscellaneous

Free Float
39,941,000
Market Cap
$307.74 million
Optionable
Optionable
Beta
1.12
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Karen ZaderejMs. Karen Zaderej (Age 61)
    Chairman, President & CEO
    Comp: $852.18k
  • Mr. Peter J. Mariani (Age 59)
    Executive VP & CFO
    Comp: $532.5k
  • Mr. Michael Donovan (Age 58)
    Vice President of Operations
    Comp: $406.02k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 68)
    Chief Research & Development Officer
    Comp: $540.91k
  • Ed Joyce
    Director of Investor Relations
  • Mr. Marc A. Began (Age 55)
    Executive VP, General Counsel & Chief Compliance Officer
  • Ms. Doris Quackenbush
    Vice President of Sales
  • Mr. Jens Schroeder Kemp
    Chief Marketing Officer
  • Mr. Erick DeVinney (Age 47)
    Vice President of Peripheral Nerve Science and Clinical Innovation














AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price target for 2024?

4 brokers have issued twelve-month price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2023?

AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN stock has decreased by 28.4% and is now trading at $7.15.
View the best growth stocks for 2023 here
.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 33.3% from the October 31st total of 1,620,000 shares. Based on an average trading volume of 433,100 shares, the days-to-cover ratio is presently 5.0 days. Currently, 5.3% of the company's stock are sold short.
View AxoGen's Short Interest
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The medical equipment provider earned $41.27 million during the quarter, compared to the consensus estimate of $40 million. AxoGen had a negative trailing twelve-month return on equity of 23.44% and a negative net margin of 15.26%.

What ETF holds AxoGen's stock ?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tocqueville Asset Management L.P. (2.18%), Northern Trust Corp (0.94%), Ameriprise Financial Inc. (0.69%), Essex Investment Management Co. LLC (0.69%), Legal & General Group Plc (0.43%) and Acadian Asset Management LLC (0.42%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -